ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.42 USD
-0.03 (-7.30%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.42 0.00 (1.13%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for ASLAN Pharmaceuticals Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -44.09 | -51.28 | -31.59 | -16.97 | -46.66 |
Depreciation/Amortization & Depletion | 0.35 | 0.33 | 0.28 | 0.30 | 0.45 |
Net Change from Assets/Liabilities | -2.95 | 9.35 | -4.12 | -0.10 | -3.49 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.05 | 3.19 | 1.43 | 1.72 | 23.90 |
Net Cash From Operating Activities | -46.64 | -38.41 | -34.00 | -15.05 | -25.80 |
Property & Equipment | -0.01 | -0.03 | -0.04 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.09 | 0.02 | 0.00 | 0.00 |
Other Investing Activities | 0.28 | 0.35 | -0.01 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.27 | 0.41 | -0.03 | 0.00 | 0.01 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 19.66 | 0.00 | 102.60 | 7.64 | 14.76 |
Issuance (Repayment) of Debt | -12.00 | 5.00 | 12.22 | 0.00 | 3.25 |
Increase (Decrease) Short-Term Debt | -0.31 | -0.28 | -0.38 | -0.24 | -0.24 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 3.37 | 0.00 | -4.58 | -0.23 | 1.33 |
Net Cash from Financing Activities | 10.72 | 4.72 | 109.87 | 7.17 | 19.09 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -35.65 | -33.27 | 75.84 | -7.88 | -6.71 |
Cash at Beginning of Period | 56.90 | 90.17 | 14.32 | 22.20 | 28.91 |
Cash at End of Period | 21.25 | 56.90 | 90.17 | 14.32 | 22.20 |
Diluted Net EPS | -2.69 | -3.68 | -2.40 | -2.00 | -7.25 |
Fiscal Year End for ASLAN Pharmaceuticals Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -44.09 | 0.00 | -20.93 | 0.00 |
Depreciation/Amortization & Depletion | NA | 0.35 | 0.00 | 0.18 | 0.00 |
Net Change from Assets/Liabilities | NA | -2.95 | 0.00 | -16.80 | 0.00 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.05 | 0.00 | 0.22 | 0.00 |
Net Cash From Operating Activities | NA | -46.64 | 0.00 | -37.33 | 0.00 |
Property & Equipment | NA | -0.01 | 0.00 | -0.01 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.28 | 0.00 | 0.28 | 0.00 |
Net Cash from Investing Activities | NA | 0.27 | 0.00 | 0.27 | 0.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 19.66 | 0.00 | 17.83 | 0.00 |
Issuance (Repayment) of Debt | NA | -12.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -0.31 | 0.00 | -0.15 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 3.37 | 0.00 | 3.43 | 0.00 |
Net Cash from Financing Activities | NA | 10.72 | 0.00 | 21.10 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -35.65 | 0.00 | -15.96 | 0.00 |
Cash at Beginning of Period | NA | 56.90 | 0.00 | 56.90 | 0.00 |
Cash at End of Period | NA | 21.25 | 0.00 | 40.94 | 0.00 |
Diluted Net EPS | NA | -0.73 | -0.56 | -0.11 | -1.29 |